Looking to support positron emission tomography (PET) imaging techniques for the diagnosis and treatment of prostate cancer, PETNET Solutions will provide clinical researchers in the greater New York City area with access to gallium-68-labelled prostate-specific membrane antigen (68Ga-labelled PSMA). The wholly owned subsidiary of Siemens Medical Solutions USA, Malvern, Pa, PETNET Solutions will offer the investigational tracer for use in PET/computed tomography (PET/CT) clinical trials.
Prostate cancer is the second most frequently diagnosed cancer among men in the United States. An estimated 220,000 men are expected to be diagnosed with the disease this year, with approximately 15,000 in New York state alone.¹ Recent hypotheses regarding the variation and diversity of prostate cancer suggest that all variants should not be treated equally,² which, according to the company, underscores a need for expanded classification of the disease through imaging and biopsy methods.
For more information, visit PETNET Solutions.
- Cancer Facts & Figures 2015. American Cancer Society. 2015. Accessed July 22, 2015 via http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/
- Wyatt A.W., Mo, F., Wang, Y., & Collins, C.C. (2013). The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing. Asian J Androl. 15(3), 301-8.
Get AXIS e-newsletters free. Subscribe here.